Drug Trial Radar · NCT06106308
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Actual
Start
Feb 27, 2024
Primary completion
Apr 16, 2027
Study completion Apr 16, 2027
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Conditions
- Metastatic Colorectal Cancer
- CRC
- KRAS/NRAS Mutation
Interventions
OnvansertibDrug
Oral capsule
FOLFIRIDrug
FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
BevacizumabDrug
IV Infusion
FOLFOXDrug
FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 1 year
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Phoenix, Arizona
The University of Arizona Cancer Center
Tucson, Arizona
St. Bernards Medical Center
Jonesboro, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Pacific Cancer Medical Center
Anaheim, California
Comprehensive Blood and Cancer Center - Bakersfield
Bakersfield, California
Orange Coast Memorial Medical Center
Fountain Valley, California
UC San Diego Moores Cancer Center
La Jolla, California
Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California
Sharp Memorial Hospital
San Diego, California
Torrance Memorial Physician Network - Cancer Care and Infusion Center
Torrance, California
PIH Health
Whittier, California
Memorial Cancer Institute
Hollywood, Florida
Mayo Clinic - Florida
Jacksonville, Florida
Cleveland Clinic Martin Health
Stuart, Florida
Kaiser Permanente
Honolulu, Hawaii
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
The University of Kansas Cancer Center - Westwood
Westwood, Kansas
Cancer Center of Kansas
Wichita, Kansas
Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion
Grand Rapids, Michigan
Mayo Clinic Cancer Center
Rochester, Minnesota
Saint Luke's Hospital
Kansas City, Missouri
Washington University School of Medicine Center for Advanced Medicine
St Louis, Missouri
CCCN
Las Vegas, Nevada
Manhattan Hematology Oncology (MHO) Research Foundation, Inc.
New York, New York
Trihealth Kenwood
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Lehigh Valley Health Network
Allentown, Pennsylvania
West Cancer Clinic
Germantown, Tennessee
Oncology Consultants, PA
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
Inova Schar Cancer Institute
Fairfax, Virginia
VCU Massey Cancer Center
Richmond, Virginia
Virginia Mason Medical Center
Seattle, Washington
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.